(Follow-up Disclosure) Notice of Completion of Acquisition of Shares of Radianceware Co., Ltd. (Making it a Subsidiary)

The company decided at its Board of Directors meeting held on March 19, 2026, to acquire 100% of the common stock of Radianceware Co., Ltd. (Headquarters: Kodama-gun, Saitama; Representative Director: Yoshio Nakajima; hereinafter, 'Radianceware') to make it a subsidiary. We are pleased to announce that on April 1, 2026, we acquired the shares and completed the subsidiary process. As of the same date, Representative Director Yoshio Nakajima resigned and assumed the post of Consultant.

This acquisition of Radianceware is the second phase of our strategic M&A aimed at maximizing profits in the medical business. By incorporating a strong customer base and sales network in the Tokyo metropolitan area and northern Kanto region into the Group, we will accelerate the transition to a Group direct sales model. As a growth strategy after integration, we will build up recurring (stock-type) revenue by expanding the provision of maintenance and services based on the company's approximately 475 existing medical system-related customers.

Radianceware has a track record of selling diverse medical systems as a distributor. While leading to continuous revenue through maintenance and operation support after introduction, we will also promote the introduction of products centered on MightyChecker® EX from our group company, AIS Co., Ltd. Furthermore, we will promote proposals for incorporating 'Mighty QUBE® Hybrid' into electronic medical records handled by Radianceware to expand sales and contribute to improving the profitability of medical institutions, ensuring medical safety, and addressing work-style reforms for doctors.

Through these initiatives, in addition to improving the unit price per facility, we will simultaneously achieve efficiency through the integration of sales channels and the expansion of recurring revenue, leading to improved profitability on a consolidated basis. Our group will continue to steadily promote such strategic investments and integration of business foundations to contribute to solving the social issue of personnel shortages in medical institutions and establish our position as a leading company in the medical field, working to maximize corporate value sustainably.